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Objective: We sought to determine the target populations and drug efﬁcacy, toxicity, cost, and initiation
age thresholds under which a pharmacologic regimen for knee osteoarthritis (OA) prevention could be
cost-effective.
Design: We used the Osteoarthritis Policy (OAPol) Model, a validated state-transition simulation model
of knee OA, to evaluate the cost-effectiveness of using disease-modifying OA drugs (DMOADs) as pro-
phylaxis for the disease. We assessed four cohorts at varying risk for developing OA: (1) no risk factors,
(2) obese, (3) history of knee injury, and (4) high-risk (obese with history of knee injury). The base case
DMOAD was initiated at age 50 with 40% efﬁcacy in the ﬁrst year, 5% failure per subsequent year, 0.22%
major toxicity, and annual cost of $1,000. Outcomes included costs, quality-adjusted life expectancy
(QALE), and incremental cost-effectiveness ratios (ICERs). Key parameters were varied in sensitivity
analyses.
Results: For the high-risk cohort, base case prophylaxis increased quality-adjusted life-years (QALYs) by
0.04 and lifetime costs by $4,600, and produced an ICER of $118,000 per QALY gained. ICERs >$150,000/
QALY were observed when comparing the base case DMOAD to the standard of care in the knee injury
only cohort; for the obese only and no risk factors cohorts, the base case DMOAD was less cost-effective
than the standard of care. Regimens priced at $3,000 per year and higher demonstrated ICERs above cost-
effectiveness thresholds consistent with current US standards.
Conclusions: The cost-effectiveness of DMOADs for OA prevention for persons at high risk for incident OA
may be comparable to other accepted preventive therapies.
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Knee osteoarthritis (OA) is a prevalent disease characterized by
chronic pain and functional limitation. Affecting nearly 9.3 million
American adults1 and accounting for $27 billion annually in
aggregate health care expenses in the US2, the burden of knee OA
on our country’s population and resources is profound. With an
increasing proportion of older adults in the country, an obesity
epidemic, and the growing prevalence of knee injuries, the growth
of this clinical and economic burden shows few signs of slowing
down3e6.td. All rights reserved.
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important subject of study, particularly because currently there is
no medical treatment to reverse or stop the progression of OA.
Analyses evaluating the role of pharmacologic prevention of knee
OA have yet to appear in published literature, even though the
development of pharmacologic regimens aimed at preventing
incident knee OA has been posed as an important research prior-
ity7,8. This lack of effective pharmacologic prophylaxis for persons
at high risk for knee OA represents a critical gap in the current set of
therapeutic options.
We sought to conduct an evaluation of pharmacologic prophy-
laxis as a method of preventing the occurrence of symptomatic
knee OA in populations at varying levels of risk for the development
of the disease. Using a novel model-based approach that parallels
our previous analysis of the cost-effectiveness of disease-modifying
OA drugs (DMOADs) for knee OA treatment9, we varied the efﬁcacy,
toxicity, cost, and age of initiation associated with the pharmaco-
logic regimen in order to determine the conditions under which e
and the patients for whom e the use of prophylactic DMOADs may
be cost-effective.Methods
Analytic overview
We used the Osteoarthritis Policy (OAPol) Model, a validated
computer simulation model of knee OA natural history and
management, to examine the cost-effectiveness of DMOADs used
for knee OA prevention in persons with established knee OA risk
factors: obesity and history of knee injury10e12. We considered
four cohorts: (1) a ‘no risk factors’ cohort that was non-obese and
had no history of knee injury, (2) an ‘obese only’ cohort in which
all subjects were obese but did not have a history of knee injury,
(3) a ‘knee injury only’ cohort in which all subjects had a history
of knee injury but were non-obese, and (4) a ‘high-risk’ cohort
where subjects were both obese and had a history of knee injury.
Each cohort was initialized with no knee OA at baseline. We
varied the age of DMOAD initiation from 30 to 60 years.
We established the levels of efﬁcacy, toxicity, and cost required
for prophylactic DMOADs to reach speciﬁc cost-effectiveness
thresholds.
The primary outcomes were quality-adjusted life expectancy
(QALE) and lifetime medical costs. Cost-effectiveness for each
pharmacologic prevention strategy was then assessed by calcu-
lating incremental cost-effectiveness ratios ((ICERs), or the ratios of
a change in cost over a change in QALE) between strategies un-
dergoing and not undergoing the preventative DMOAD regimen. In
accordance with the Recommendations of the US Panel on Cost-
Effectiveness in Health and Medicine, costs and quality-adjusted
life-years (QALYs) were discounted at 3% per year13. Strategies
that resulted in an increase in cost with a decrease in QALE were
labeled “Dominated.”The OAPol Model
The OAPol Model is a validated, state-transition computer
simulationmodel of the natural trajectory andmanagement of knee
OA14,15. Themodel operates as aMonteCarlo simulationwith annual
cycles that draws subjects from user-deﬁned distributions for
demographic (e.g., age, sex, and race) and clinical (e.g., body mass
index (BMI), knee OA incidence and severity, and the incidence of
comorbidities) characteristics. Obesity was deﬁned as having a BMIof greater than or equal to 30 kg/m2 and varied in the model
according to a subject’s current BMI, age, sex, and race/ethnicity.
History of knee injury was incorporated into the model using rela-
tive risks for incident knee OA following knee injury reported in
published literature12. Comorbidities considered by the model
included cancer, coronary heart disease (CHD), chronic obstructive
pulmonarydisorder, diabetesmellitus, andnon-OAmusculoskeletal
disorders. Prevalence and incidence rates for all diseases were
dependent on the subject’s age, race, sex, and obesity status16e18.
Cancer, CHD, and obesity each had an associated relative risk of
mortality; the derivation of this relative risk of mortality due to
cancer, CHD, and obesity has been previously published15. Under-
lying mortality rates were derived from 2006 CDC life tables19.
The model tracks every subject until death, allowing them to
transition between health states deﬁned by knee OA severity, the
presence of knee pain, obesity, and comorbidities14,15. As subjects
pass through these health states, they accumulate costs associated
with OA-related and non-OA related medical care (in 2010 United
States Dollars (USD)) as well as changes in quality of life (QOL) that
affect a subject’s QALE. Annual medical costs not attributable to OA
were determined by a subject’s number of comorbidities, age, and
pain status. Annual QOL estimates were formulated in terms of
preference-based measures of utility ranging from 0.0 to 1.0, with
1.0 representing perfect health and 0.0 representing death20. The
data for baseline QOL were derived from National Health and
Nutrition Examination Survey (NHANES) 2005e08 using the Diehr
transformation and from Losina et al. 200917,18,21,22. Values for QOL
utilities were stratiﬁed according to obesity status, pain status, age,
and the number of comorbidities; previous knee injury was not
incorporated into baseline QOL. Further details on the OAPol Model
are published elsewhere9,14,15,23.Cohort characteristics
Our analysis evaluated the use of prophylaxis in four hypo-
thetical cohorts characterized by varying degrees of risk for the
development of symptomatic knee OA: ‘no risk factors’ (non-obese
and no history of knee injury), ‘obese only’ (obese and no history of
knee injury), ‘knee injury only’ (history of knee injury and non-
obese), and ‘high-risk’ (both obese and with history of knee
injury). Each cohort was initialized with a mean age of 27.5 years
(standard deviation 0.83 years). The 2009 US Census indicated that
49% of this age group was female, 64% were non-Hispanic White,
20% were Hispanic, and 16% were non-Hispanic Black24.
Annual direct medical costs ranged from $1,302 for people ages
25e34with 0 or 1 comorbidities to $18,673 for persons over the age
of 80 with greater than 3 comorbidities17,18,25,26. We incorporated
an additional annual cost of $204 for subjects in pain both on and
off regimens to manage OA to account for the cost of pain medi-
cation26,27. QOL utilities ranged from 0.96 for individuals who were
not obese, had 0e1 comorbidities, and experienced no OA pain to
0.66 for individuals who were obese, had 4e5 comorbidities, and
were in pain. All subjects with advanced knee OA, deﬁned as a
KellgreneLawrence (KeL) radiographic grade of 3 or 4, were
assigned an annual weighted utility of 0.69022. All cost and QOL
utility values are presented in Table I.OA incidence
We stratiﬁed annual knee OA incidence rates by both obesity
status and history of previous knee injury. Base OA incidence
rates were derived from OA prevalence data from the National
Health Interview Survey (NHIS) 2007e2008 stratiﬁed by non-
Table I
Model inputs
Parameter (applied annually) Overall estimates Sources
Incidence of knee
OA (annual %)
‘No risk factors’
cohort
‘Obese only’
cohort
‘Knee injury
only’ cohort
‘Obese with knee
injury’ cohort
Wilder et al. 200212
NHANES 2003e200428
Losina et al. 201328Age groups Male Female Male Female Male Female Male Female
25e34 0.09 0.12 0.16 0.29 0.78 0.84 1.28 2.05
35e44 0.10 0.13 0.16 0.31 0.85 0.90 1.28 2.21
45e54 0.15 0.23 0.30 0.41 1.24 1.66 2.50 2.93
55e64 0.27 0.38 0.49 0.79 2.20 2.72 4.02 5.55
65e74 0.19 0.25 0.29 0.35 1.57 1.80 2.38 2.48
75e84 0.17 0.18 0.23 0.30 1.37 1.28 1.86 2.16
85þ 0.17 0.18 0.23 0.30 1.37 1.28 1.86 2.16
QOL utilities
All subjects with
severe OA
(KeL 3 or 4)
0.690 NHANES 2005e200617
NHANES 2007e200818
Non-obese Obese
Age groups Number of comorbidities Number of comorbidities
No knee pain 0e1 2e3 4e5 0e1 2e3 4e5
25e44 0.955 0.903 0.662 0.921 0.870 0.662
45e64 0.952 0.901 0.662 0.918 0.867 0.662
65þ 0.943 0.891 0.662 0.909 0.858 0.662
Knee pain
25e44 0.814 0.721 0.662 0.781 0.688 0.662
45e64 0.806 0.713 0.662 0.773 0.679 0.662
65þ 0.884 0.791 0.662 0.850 0.757 0.662
Annual direct medical costs* (in 2010 USD)
Age groups 0 e 1
Co-morbidities
2 e 3
Co-morbidities
4 e 5
Co-morbidities
25e34 $1,302 $6,652 $12,506 NHANES 2005e200617
NHANES 2007e200818
Pope et al. 200425
35e44 $1,814 $7,165 $13,019
45e49 $2,431 $7,755 $11,751
50e54 $2,432 $7,755 $11,751
55e59 $3,239 $8,232 $12,902
60e64 $3,940 $8,933 $13,602
65e69 $4,198 $8,856 $15,366
70e74 $4,888 $9,547 $16,056
75e79 $5,712 $10,371 $16,881
80þ $7,505 $12,163 $18,673
DMOAD characteristics
Base case values Ranges considered in
sensitivity analyses
Treatment efﬁcacy in the ﬁrst year 40% 30e70%
Failure of treatment in subsequent years 5% 1e10%
Minor toxicity: First year (subsequent years) 9.50% (7.27%) (Not varied)
Major toxicityy 0.22% 0e0.44%
Annual cost $1,000 $300e$3,000
Age at which subjects begin taking DMOADs 50 30, 40, 50, 60
* This excludes pain management. Acknowledging that patients may use analgesics to control painful knee OA, an annual cost of $203.80 was added for patients with
symptomatic knee OA26,27.
y Major toxicity values were based on reported toxicity of selective NSAIDs (0.44% incidence, 10% mortality)34.
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430 417obese and obese populations16,28. To account for the impact of
previous knee injury on OA incidence, we stratiﬁed our cohorts
according to our derivations of the prevalence of knee injury in
the general population using NHANES 2003e04 data29. We then
adjusted OA incidence rates with a relative risk of knee OA
incidence due to knee injury published by Wilder et al. (8.3 for
males and 7.2 for females)12. Our incidence rates stratiﬁed by
obesity and previous knee injury were then further stratiﬁed by
age and sex; these estimates are presented in Table I.
Regimens for prophylaxis and OA treatment
In this analysis, we evaluated the cost-effectiveness of using
DMOADs compared to the use of no prophylactic regimen for
the prevention of symptomatic knee OA. Fig. 1 provides a basic
outline of the health states and treatment sequence experi-
enced by subjects undergoing a DMOADs regimen and subjectsundergoing the standard of care (no prophylaxis). All subjects
entered the model without OA. Following the diagnosis of
symptomatic knee OA, OA pain was managed with a series of
nonsurgical and surgical regimens described in greater detail
under Guideline-concordant OA care. Prophylaxis was dis-
continued for those diagnosed with knee OA. The preventative
DMOAD regimen and standard of care regimens contributed to
changes in costs and QALE over time in the model. Beyond the
impact of these regimens on cost and QOL, these regimens had
associated risks of toxicity. In the incidence of an adverse event,
subjects were evaluated for whether or not the incurred
toxicity was major or minor. For example, while subjects had a
little over 24% chance of incurring any toxicity due to cortico-
steroid injections30, 99.995% of these toxicities were minor
(e.g., ﬂare) and 0.005% were major (e.g., sepsis). Thus in all
subjects, 24%31 had a minor toxicity and 0.0013%32 had a major
toxicity in one year of treatment. Medical costs and decrements
No OA
OA
Nonsurgical
Regimens 1 and 2
TKR / Post
TKR
Death
No OA No OADMOADs
OA
DMOADs Regimen 
Terminated
OA
Nonsurgical
Regimens 1 and 2
Death
TKR / Post
TKR
DMOADs Regimen for OA Prevention
Guideline Concordant Care for OA Management
Fig. 1. Sequence of OA prevention, incidence, and treatment.
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430418to a subject’s health-related QOL were substantially greater for
major adverse events, which imparted an increased risk of
mortality.
Subjects discontinued use of the pharmacologic prophylaxis
when any of the following occurred: (1) death, (2) diagnosis of
symptomatic knee OA, or (3) major toxicity. DMOAD efﬁcacy was
deﬁned by a reduction in OA incidence. Notably, undiagnosed
incident radiographic OA did not constitute termination from the
prevention regimen; subjects continued to incur annual costs and
minor toxicities until the development of symptomatic pain and
the subsequent observation of the disease. The model evaluated
efﬁcacy in the ﬁrst year of OA prevention as well as the probability
that an efﬁcacious regimen would fail in subsequent years
(deﬁned as late failure). Late failure could arise due to lack of
adherence, tolerance, or other mechanisms. While major toxicity
led to a subject’s removal from the preventative regimen, minor
toxicity did not result in DMOAD discontinuation and had no
impact on its likelihood of preventing OA in subsequent years
(Fig. 2).
Base case DMOAD characteristics
In line with recommendations made by the Panel in Cost-
effectiveness Analyses in Health and Medicine, we created a
‘base case’ DMOAD regimen to evaluate the combination of drug
efﬁcacy, cost, toxicity, and age of initiation that would be most
likely observed in a clinical setting (these are summarized in
Table I)33. For this analysis, we assumed a base case prophylaxis
regimen with an initiation age of 50 and a 40% probability of
preventing OA incidence in the ﬁrst year. For those who experi-
enced this early efﬁcacy, we assumed that 5% of subjects would
experience late failure and thus develop knee OA in subsequent
years. We assumed the risk of major toxicity from prophylaxis
would be about half of the risks associated with NSAIDs, giving
our base case a 0.22% annual probability of major toxicity34. Forour base case, we settled on $1,000 as a mid-range annual cost
based on the annual cost of an NSAID prescription26.Guideline-concordant OA care
Following OA incidence in the model, subjects became eligible
to receive guideline-concordant care to manage knee OA-related
pain. These subjects received a sequence of pain management
interventions (Fig. 1): Regimen 1 (physical therapy, assistive de-
vices, NSAIDs, and acetaminophen), Regimen 2 (intra-articular
corticosteroid injections), Regimen 3 (primary total knee
replacement, or TKR), and Regimen 4 (revision TKR)35e39. Subjects
became eligible for each regimen upon the failure of the subse-
quent regimen in the sequence; uptake of the next regimen was
deﬁned by eligibility, offer, and acceptance rates. Data describing
the efﬁcacy, toxicity, and annual costs associated with these knee
OA management strategies for ﬁrst and subsequent years of
treatment were derived from literature and are presented in re-
ports published previously by these authors9,15. Costs ranged from
$437 for corticosteroid injections26,27,40 to $24,631 for revision
TKR40e42. Pain relief in the ﬁrst year ranged from 64% for NSAIDs
and corticosteroid injections27,43 to 86% for primary TKR44,45. The
likelihood of treatment-associated toxicities ranged from 3.33% for
NSAIDs34,46e48 to 24% for corticosteroid injections30.Sensitivity analyses
To address uncertainty in our assumptions regarding key
DMOADs characteristics, in concordance with recommendations of
the US Panel on Cost-Effectiveness in Health and Medicine and the
International Society for Pharmacoeconomics and Outcomes
Research Task Force on Good Modeling Practice, we conducted
multilevel deterministic sensitivity analyses49. These analyses
provide insight into the impact of uncertainty and highlight
No
For subjects who have been determined to
live and have not yet developed knee OA
Accumulate
DMOAD costs
Incident pain
due to OA Yes
Subject removed
from DMOADs in
following cycle
Subject remains
on DMOADs
Toxicity
MajorContinue onDMOADs
No
Death
End Subject
Life Cycle
Yes
Yes
Subject receives
DMOADs
QoL decrease
Costs increase
QoL decrease
Costs increase
Yes
No
No
Continue
Life Cycle
Proceed with
standard of care
for OA treatment
No
Incident pain
due to OA Yes
Fig. 2. DMOADs as prevention in the OAPol Model.
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430 419scenarios inwhich small changes in model input data produce large
changes in model results.
To determine the impact of efﬁcacy, major toxicity, annual cost,
and age of initiation on the cost-effectiveness of a preventative
DMOAD regimen for knee OA, we conducted a series of two-way
sensitivity analyses using a range of values for each DMOAD char-
acteristic (ranges listed in Table I).
We varied early efﬁcacy from 30% to 70% and late failure
from 1% to 10% given that the prophylaxis was efﬁcacious in
the ﬁrst year. Because knee OA incidence is dependent on
subject age, we evaluated the impact initiating the DMOAD
regimen in subjects aged 30e60 in 10-year increments. DMOAD
initiation at a younger age potentially generates higher cumu-
lative costs while exposing subjects to drug toxicities for a
longer period of time. However, later initiation potentially
misses a tangible number of OA cases, especially in high-risk
groups. Only those who had not been diagnosed with symp-
tomatic knee OA were eligible for the DMOAD regimen at the
given age.To evaluate the impact of prophylaxis toxicity, we varied
annual DMOAD major toxicity from none to 0.44%, a level
consistent with the toxicity of selective NSAIDs34. Major toxicity
accounted for potential upper gastrointestinal complications,
and carried a probability of death of 2.93%50. We did not
consider cardiovascular toxicities because drugs with such
adverse events would not likely be used in a prophylactic
setting. DMOAD minor toxicity (dyspepsia, diarrhea, rash, etc)
was derived from the toxicity associated with non-selective
NSAIDs; risk of minor toxicity in the ﬁrst and subsequent
years of the regimen at 9.50% and 7.27%, respectively43,46. We
assumed major gastrointestinal toxicity from prophylaxis had an
associated cost of $9,40850, while minor toxicity had an asso-
ciated cost of $4751.
DMOAD cost for knee OA prophylaxis was based on the cost of
antihypertensives (approximately $400 annually for ge-
nerics)52,53, cholesterol-lowering agents (approximately $600
annually for generics)54, and NSAIDS (approximately $1,000
annually, on average)26. We considered low- and high-cost
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430420scenarios in our sensitivity analyses, varying the annual cost of
the DMOAD regimen from $300 to $3,000 per year (Table I). In
addition to considering costs of the DMOAD and its associated
toxicities, we accounted for two ofﬁce visits in the ﬁrst year
($224 total) and one ofﬁce visit in every subsequent year ($93),
as well as one X-ray in the ﬁrst year ($41) of the regimen40,55. For
all costs related to the DMOADs regimen, including medication
costs, follow-up visits, and X-rays, we made the conservative
assumption that costs would be incurred in the system even in
the case of imperfect adherence.Results
Base case analysis
Clinical beneﬁts of DMOADs regimen
In the absence of a preventative DMOAD regimen, using cur-
rent standard of care practices led to an estimated discounted
QALE of 25.0 QALYs for the ‘non-obese without knee injury’
cohort (undiscounted: 49.5 QALYs), 23.5 QALYs for the ‘obese
only’ cohort (undiscounted: 45.7 QALYs), 24.5 QALYs for the
‘knee injury only’ cohort (undiscounted: 48.2 QALYs), and 22.7
QALYs for the ‘obese with knee injury’ cohort (undiscounted:
43.8 QALYs).
For the high-risk ‘obese with knee injury’ cohort, all DMOAD
scenarios showed an increase in QALE over the standard of care.
The base case preventative DMOAD increased discounted QALE
by 0.04 QALYs (undiscounted: 0.13 QALYs) from the standard of
care.
For the ‘knee injury only’ cohort, the base case DMOAD regimen
increased discounted QALE by 0.03 QALYs from the standard of care
(undiscounted: 0.10 QALY increase). For the ‘obese only’ cohort, the
base case did not change discounted QALE and caused a decrease in
undiscounted QALE by 0.01 QALYs from the standard of care. For
the ‘non-obese without knee injury’ cohort, discounted QALE
decreased by 0.01 QALYs from the standard of care (undiscounted:
0.03 QALY decrease).Table II
Incremental cost-effectiveness ratios for base case DMOADs and other preventative regi
Disease Target population
OA Patients who are obese and have a history of knee inju
Patients who are non-obese and have a history of kne
Patients who are obese and have no history of knee in
Patients who are non-obese and have no history of kn
Non-OA chronic diseases
Breast cancer Women who were at a higher risk of
breast cancer
Ages 35
Ages 50
Ages 60
Cardiovascular events Patients over 35 years of age with coronary disease
Major Vascular Events (MVE)z Patients aged 55 with blood total cholesterol
concentrations  135 mg/dL and medical
history of coronary disease, cerebrovascular
disease, other occlusive arterial disease,
diabetes mellitus, or treated hypertension
5-year M
of treatm
5-year M
of treatm
Myocardial infarction Patients with past myocardial infarction (mean age 62
Stroke Patients 65 years of age with nonvalvular atrial ﬁbrilla
and one additional risk factor
* ICERs reported as incremental costs in 2010 USD per QALY gained compared to guid
y Base Case DMOADs were initiated at age 50, had a 40% probability of early efﬁcacy,
toxicity.
z For example, a nonfatal myocardial infarction or coronary death, any stroke, or revaEconomic outcomes of pharmacologic knee OA prophylaxis
In the absence of any preventative regimen, discounted lifetime
costs from age 27 were estimated to be $80,800 for the ‘non-obese
without knee injury’ cohort (undiscounted lifetime costs:
$226,200), $85,400 for the ‘obese only’ cohort (undiscounted:
$239,300), $83,500 for the ‘knee injury only’ cohort (undiscounted:
$234,000), and $90,400 for the ‘obese with knee injury’ cohort
(undiscounted: $252,600).
The base case DMOAD regimen increased discounted lifetime
costs in the ‘obese with knee injury’ cohort by $4,600 over the
standard of care. For the ‘knee injury only,’ ‘obese only,’ and ‘non-
obese without knee injury’ cohorts, the base case DMOAD regimen
increased discounted lifetime medical costs by $7,100, $9,200, and
$10,200, respectively.
Cost-effectiveness of DMOADs for OA prevention
ICERs for OA prophylaxis compared to no-prophylaxis for the
‘obese with knee injury’ cohort and ‘knee injury only’ cohort are
shown in Table II. For the ‘obese with knee injury’ cohort, the base
case DMOAD regimen resulted in an ICER of $118,000 per QALY
gained (Fig. 3). The ‘knee injury only’ cohort resulted in an ICER of
$257,200/QALY (Fig. 4). In the ‘obese only’ and ‘non-obese without
knee injury’ cohorts, the DMOAD prevention regimen was
dominated.
Sensitivity analyses
In addition to evaluating DMOAD cost-effectiveness under base
case parameters, we evaluated the regimen under a range of values
for annual cost, efﬁcacy, toxicity, and age of DMOAD initiation. The
results of these sensitivity analyses for the ‘obese with knee injury’
and ‘knee injury only’ cohorts are illustrated in Figs. 3 and 4 and
Technical Appendix Figs. 1 and 2. For both cohorts, DMOADs for OA
prevention became less cost-effective under the following condi-
tions: increasing annual DMOAD cost from $300 to $3,000,
decreasing early efﬁcacy from 70% at maximum to 30% at mini-
mum, increasing the probability of late failure from 1% to 10%, and
increasing major toxicity from no toxicity [Technical Appendix,
Figs. 1(a) and 2(a)] to 0.44% [Technical Appendix, Fig. 1(b) andmens for chronic disease
Prophylaxis ICERs* Source
ry Base case DMOADy $118,000
e injury $257,200
jury Dominated
ee injury Dominated
to 49 Tamoxifen $68,500 Noe et al. 199959
to 59 $113,200
to 69 $124,100
Aspirin $16,400 Gaspoz et al. 200278
Clopidogrel $46,200
VE risk at initiation
ent: 5%
Simvastatin $23,300 Heart Protection
Study Collaborative
Group 200979VE risk at initiation
ent: 40%
$5,300
.3 years) Amiodarone $103,100 Sanders et al. 200160
Implantable Cardioverter
Deﬁbrillator
$181,000
tion Warfarin sodium Cost-saving Gage et al. 199580
eline-concordant care. ICERs are rounded to the nearest $100/QALY.
5% probability of late failure, annual cost of $1,000, and posed a 0.22% risk of major
scularization procedure.
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $39,100 $92,800 $298,300 30% $120,700 $269,200 $833,000 30% $236,200 $520,700 ########
40% $26,200 $56,000 $131,400 40% $84,200 $166,300 $369,000 40% $166,800 $323,600 $709,600
50% $19,200 $40,600 $84,700 50% $64,800 $123,300 $241,800 50% $129,500 $240,600 $467,800
60% $14,800 $31,200 $62,000 60% $52,200 $97,000 $180,800 60% $105,700 $190,400 $350,800
70% $12,000 $25,200 $48,600 70% $44,500 $79,700 $144,000 70% $90,500 $158,300 $281,100
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $37,500 $80,600 $240,600 30% $118,600 $237,000 $678,800 30% $234,100 $460,400 ########
40% $24,900 $49,200 $114,500 40% $82,400 $150,700 $326,300 40% $163,500 $292,900 $630,400
50% $17,900 $34,300 $71,000 50% $61,900 $108,500 $208,700 50% $124,200 $214,300 $405,300
60% $13,600 $26,300 $52,800 60% $50,600 $86,200 $160,100 60% $103,600 $171,900 $314,400
70% $11,000 $21,700 $41,900 70% $42,800 $71,700 $128,400 70% $88,400 $143,000 $250,800
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $35,900 $61,200 $118,800 30% $115,200 $183,700 $334,800 30% $229,200 $361,500 $644,500
40% $22,300 $36,800 $69,200 40% $78,400 $118,000 $207,700 40% $156,100 $234,700 $404,300
50% $17,200 $27,700 $47,400 50% $60,600 $89,000 $142,300 50% $123,200 $179,000 $280,000
60% $12,800 $20,600 $34,100 60% $48,600 $72,300 $109,400 60% $100,700 $145,400 $217,700
70% $9,900 $17,000 $27,900 70% $41,600 $59,700 $89,400 70% $87,000 $121,400 $179,800
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $64,300 $94,200 $136,900 30% $193,000 $282,800 $411,000 30% $381,000 $543,900 $790,500
40% $36,000 $52,400 $75,600 40% $127,700 $157,300 $227,000 40% $252,100 $310,700 $436,600
50% $26,500 $39,100 $47,500 50% $94,100 $117,300 $142,600 50% $190,700 $231,600 $281,600
60% $20,100 $26,000 $39,900 60% $71,200 $92,300 $119,700 60% $144,200 $182,200 $236,300
70% $17,200 $22,300 $27,000 70% $61,000 $79,100 $95,600 70% $126,700 $160,200 $193,700
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Fig. 3. Incremental Cost-effectiveness ratios of DMOADs as prevention: ‘Obese with knee injury’ cohort; prophylaxis with 0.22% major toxicity.
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430 4212(b)]. Because regimens priced at $3,000 were either dominated or
demonstrated ICERs>$125,000/QALY in all four cohorts at all levels
of toxicity and efﬁcacy, these regimens were not shown in any
ﬁgure reporting ICERs for our sensitivity analyses.
For the ‘obese with knee injury’ cohort, decreasing the annual
cost of the DMOAD regimen from $1,000 in the base case to $300
decreased the ICER for this cohort to $36,800/QALY, assuming 0.22%
toxicity, 5% late failure, and 40% early efﬁcacy (Fig. 3). Increasing
early efﬁcacy from 40% in the base case to 70%, assuming $1,000
annual cost and 5% late failure, decreased the ICER to $59,700/QALY.
Decreasing late failure from 5% in the base case to 1% decreased the
ICER to $78,400/QALY. Decreasing annual likelihood of major
toxicity from the base case 0.22% to 0% reduced the ICER to
$108,300/QALY. Increasing the initiation age from 50 in the base
case to 60 increased the ICER to $157,300/QALY; decreasing the
initiation age to 40 and 30 increased the ICER to $150,700/QALYand
$166,300/QALY, respectively.
For the single risk factor cohorts, the preventative DMOAD
regimen resulted in lower ICERs for the ‘knee injury only’ cohort
than for the ‘obese only’ cohort overall when compared to guide-
line-concordant care. When the DMOAD regimen had 0.22% major
toxicity and was priced at $1,000 annually, the ‘knee injury only’
cohort demonstrated ICERs less than $150,000/QALY only when
early efﬁcacywas at least 50% and late failurewas at most 5%. Use of
the DMOAD regimen in the no risk factors ‘non-obese without kneeinjury’ cohort was either less effective than the standard of care or
produced ICERs greater than $150,000/QALY.
A best case prophylaxis
In addition to evaluating a base case DMOAD regimen, we
estimated the cost-effectiveness of a ‘best case’ DMOAD regimen
for the prevention of knee OA: no major toxicity, 70% early efﬁcacy
in the ﬁrst year, 1% late failure in subsequent years, and an annual
cost of $300. For the high-risk ‘obese with knee injury’ cohort,
discounted lifetime costs were $4,800 higher than for the standard
of care. The ICER associated with the best case prophylaxis for this
cohort was estimated at $10,700/QALY [Technical Appendix
Fig. 1(a)] when the regimen was initiated at age 30. When the
best case regimen was initiated at age 60 for the ‘obese with knee
injury’ cohort, discounted lifetime costs were increased by $500
and the ICER was increased to $16,500/QALY. For the ‘knee injury
only’, ‘obese only’, and no risk factors cohorts, ICERs for a best case
regimen initiated at age 30 were estimated at $25,100/QALY
[Technical Appendix Fig. 2(a)], $124,600/QALY, and >150,000/
QALY, respectively.
Discussion
This analysis evaluated the economic and clinical impact of
a regimen modeled on clinically relevant ranges for early
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $96,700 $304,000 ######### 30% $273,700 $840,900 ######### 30% $526,900 $1,606,200 #########
40% $62,400 $151,100 $620,400 40% $179,700 $419,800 $1,693,600 40% $347,700 $804,000 $3,226,800
50% $44,900 $101,200 $261,600 50% $131,700 $286,400 $723,400 50% $256,600 $550,000 $1,381,800
60% $35,500 $75,000 $173,100 60% $106,600 $215,200 $478,800 60% $207,700 $415,200 $919,100
70% $28,900 $60,100 $128,400 70% $88,500 $173,200 $356,800 70% $173,800 $335,000 $683,400
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $88,300 $221,800 $2,330,100 30% $251,600 $613,300 $6,392,700 30% $483,800 $1,169,100 #########
40% $58,000 $117,900 $364,100 40% $170,400 $333,200 $998,900 40% $329,000 $643,100 $1,919,300
50% $41,100 $80,100 $182,600 50% $124,500 $228,200 $504,800 50% $242,400 $438,800 $966,400
60% $32,800 $60,700 $128,800 60% $99,300 $176,800 $364,100 60% $195,700 $342,700 $699,800
70% $26,600 $49,600 $98,400 70% $83,100 $145,700 $280,300 70% $164,400 $282,500 $536,700
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $85,000 $150,000 $358,400 30% $242,000 $421,400 $1,006,700 30% $467,400 $813,300 $1,928,600
40% $54,000 $90,300 $180,400 40% $160,200 $257,200 $506,700 40% $313,900 $496,600 $978,000
50% $41,100 $67,600 $112,600 50% $123,600 $192,600 $320,800 50% $242,300 $374,600 $615,000
60% $31,300 $49,900 $86,500 60% $99,700 $150,200 $246,500 60% $195,400 $290,200 $476,000
70% $26,100 $40,300 $67,100 70% $83,200 $121,400 $191,200 70% $165,400 $237,900 $372,000
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $134,800 $230,500 $515,900 30% $395,600 $676,700 $1,514,600 30% $758,600 $1,278,000 $2,860,700
40% $78,800 $117,300 $157,800 40% $231,200 $344,400 $463,400 40% $449,900 $660,300 $875,200
50% $59,400 $86,600 $117,200 50% $174,500 $254,200 $344,000 50% $339,600 $487,300 $659,600
60% $46,900 $65,300 $87,400 60% $137,700 $191,800 $256,600 60% $272,000 $373,200 $492,100
70% $40,500 $53,000 $72,600 70% $122,400 $155,700 $213,300 70% $238,400 $307,500 $415,000
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Fig. 4. Incremental cost-effectiveness ratios of DMOADs as prevention: ‘Knee injury only’ cohort; prophylaxis with 0.22% major toxicity.
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430422efﬁcacy, late failure, annual cost, and toxicity based on other
pharmacologic regimens used for disease prophylaxis and OA
management. While there is no clear deﬁnition for what con-
stitutes a cost-effective medication, maximum willingness-to-
pay thresholds range from $50,000/QALY to $150,000/QALY in
literature from the United States56e58. In this report we show
that the use of a DMOAD regimen to prevent knee OA may
improve QALE at cost-effectiveness levels comparable to other
accepted therapies when used in persons at high risk for OA.
These high-risk individuals include persons with two signiﬁ-
cant risk factors for developing knee OA, such as obesity and a
history of knee injury, as well as persons with one risk factor
that signiﬁcantly increases the risk of knee OA on its own, such
as a history of knee injury. Table II shows ICERs for preventa-
tive therapies used for other prevalent chronic conditions.
While prophylaxes for stroke, major vascular events, and car-
diovascular events have lower ICERs than those for a DMOAD-
based OA prevention regimen, prophylaxis for myocardial
infarction and breast cancer have ICERs similar to those pre-
sented in this analysis59,60.
DMOAD regimens priced at $3,000 per year or higher are
unlikely to be cost-effective by current US standards, even for
persons with two knee OA risk factors. However, for a high-risk
cohort, prophylaxis is likely to be cost-effective when priced at
$300 per year. Starting this DMOAD regimen at an earlier age
demonstrated a tradeoff of a higher potential to delay knee OAonset alongside a higher potential for minor and major toxic-
ities. Despite these tradeoffs, our research shows that beginning
prophylaxis earlier in life increases QALE for these cohorts.
Though beginning a regimen later in life may cost less, starting
a prophylaxis regimen at an age after most patients are diag-
nosed with OA will not signiﬁcantly improve QALE beneﬁts.
QALE was also moderately affected by variations in the major
toxicity levels of the DMOAD regimen. The negative effect of
toxicity was greater with earlier age of prophylaxis initiation,
which was likely due to both the immediate negative impact of
experiencing a major toxicity as well as the long-term negative
effect of removing subjects from an otherwise efﬁcacious
regimen.
These results should be viewed within the context of certain
limitations and assumptions underlying the analysis. Indirect
medical costs were not considered in this economic analysis,
although they are typically substantially more than direct costs.
Furthermore, our analysis depended greatly on symptomatic
knee OA incidence data. Based on our analysis, if OA incidence
values were to increase, pharmacologic prophylaxis would
become more cost-effective. This limitation becomes particu-
larly important when considering our differentiation of the co-
horts was based on the stratiﬁcation of OA incidence rates
according to the associated added risks of obesity and previous
knee injury. This stratiﬁcation based on the merging of two risk
factors assumed that a subject at increased risk of OA due to
E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430 423obesity would be treated with a preventative pharmacologic
regimen in the same way a subject with history of knee injury
would be. In other words, we assumed subjects reporting non-
traumatic risk factors would require the same preventative
measures as those reporting traumatic risk factors. Subjects
with history of knee injury may have underlying OA-related
disease mechanisms61e63 that differ from those of
obese subjects64,65. Accordingly, our use of the same preventa-
tive regimen strategy for both groups constitutes a limitation in
our analysis. The analysis also focused entirely on pharmaco-
logic methods of OA prevention rather than behavioral or sur-
gical methods. Behavioral interventions focused on weight
management and exercise have been shown in the literature to
potentially reduce the risk for incident symptomatic knee OA as
well as potentially slow the progression of the disease by
reducing joint inﬂammation as well as the weight-bearing load
of the joint65e69. Studies evaluating the economic value of these
types of behavioral management strategies for knee OA pre-
vention may accordingly serve as another useful and important
focus for future research. An additional limitation to our analysis
was our assumption that a single pharmacologic preventative
regimen would be used. Regarding toxicity, we assumed these
agents would have similar toxicities to selective NSAIDs because
OA prophylaxis is still largely hypothetical. This analysis did not
evaluate the possibility that pharmacologic prophylaxis may be
metabolized differently in older people. Finally, the OAPol
Model does not deﬁne all pathophysiological aspects of OA and
is focused primarily on cartilage; to fully understand the impact
of prophylaxis for knee OA, it may be necessary to incorporate
the broader range of pathological and mechanical problems in
the affected knee8.
To our knowledge, this is the ﬁrst economic evaluation of the
use of pharmacologic regimens for the prevention of knee OA. We
recently published the cost-effectiveness of using DMOADs for the
treatment of knee OA upon OA incidence in Losina et al.9. In that
analysis, annual cost, suspended progression of the disease, and
pain relief were key drivers of the cost-effectiveness of using
DMOADs as treatment for the disease. Taken together, these ana-
lyses represent critical ﬁrst steps in the pre-evaluation of phar-
macologic regimens that halt or reverse the structural progression
of knee OA.While few economic analyses of DMOAD regimens exist
in the literature, some studies have evaluated the beneﬁts of
therapies to reduce knee OA incidence, including behavioral
methods leading to weight-loss and increased muscle strength
around the knee66,70. Few studies have also evaluated the use of
pharmacologic regimens for the prevention of knee OA. Recently,
statins have received attention as a potential pharmacological
method to reduce OA incidence and progression with mixed re-
sults71e76. Other recent studies have begun to evaluate biomarkers
that may identify individuals at high risk for OA77. While research
continues to investigate the efﬁcacy of methods for OA prevention,
the sum of these studies demonstrates the relevance of this and
other cost-effectiveness analyses that hope to inform how policy-
makers, clinicians, and patients collectively evaluate how to most
effectively manage medical care.
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This technical appendix provides additional results from our
examination of the cost-effectiveness of using a DMOAD
regimen for the prevention of incident symptomatic knee OA
when compared to the use of no prophylactic regimen in four
subject cohorts. In our analysis, we conducted two-way sensi-
tivity analyses evaluating the DMOAD thresholds of efﬁcacy,
major toxicity, annual cost, and age of drug initiation that
would render the prevention regimen more or less cost-
effective among subjects who possessed two, one, or no risk
factors for the development of OA. In the main body of our
report, ICERs estimated from these sensitivity analyses using
our base case level of major toxicity, 0.22%, were reported in
Figs. 3 and 4 for the ‘obese with history of knee injury’ and
‘knee injury only’ cohorts, respectively. The ﬁgures described in
this appendix below report additional ICERs estimated from
sensitivity analyses conducted on these same two cohorts
when varying DMOAD major toxicity.A. Additional results: Incremental cost-effectiveness of DMOADS
The ﬁgures included in this Technical Appendix describe addi-
tional results of our two-way sensitivity analysis examining the
impact of DMOAD major toxicity on the cost-effectiveness of the
preventative regimen. As explained in the main body of our
manuscript, the base case DMOAD was associated with a major
toxicity of 0.22%, or roughly half of the likelihood of adverse events
associated with the use of NSAIDs1.
In our sensitivity analysis of major toxicity on the cost-
effectiveness of a preventative DMOAD regimen, we varied the
likelihood of major toxicity from no toxicity to 0.44% for all four
cohorts of our analysis. In the ‘no risk factors’ cohort, estimated
ICERs were either >$150,000/QALY or dominated when toxicity
was varied from zero to 0.44%. In the single risk factor ‘obese
only’ cohort, all ICERs were similarly >$150,000/QALY or domi-
nated at both zero and 0.44% major toxicity except in the best
case DMOAD scenario at zero major toxicity (when DMOADs
were given an annual cost of $300, a 70% probability of early
efﬁcacy, and 1% chance of late failure). For this best case DMOAD
regimen in the ‘obese only’ cohort, an ICER was estimated at
$124,600/QALY.
Estimated ICERs for varying major toxicity in the high-risk
‘obese with history of knee injury’ and ‘knee injury only’ cohorts
11% 5% 10% 1% 5% 10% 1% 5% 10%
30% $32,900 $68,600 $143,800 30% $103,400 $202,500 $410,800 30% $204,200 $394,200 $788,200
40% $22,500 $46,400 $91,400 40% $75,400 $140,000 $265,200 40% $150,200 $274,100 $513,300
50% $16,800 $34,400 $64,400 50% $58,800 $106,200 $190,000 50% $118,800 $209,200 $370,000
60% $13,200 $26,700 $50,400 60% $48,500 $85,900 $149,400 60% $98,800 $170,200 $291,800
70% $10,700 $22,000 $40,000 70% $41,300 $72,400 $122,600 70% $85,200 $144,300 $241,500
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $32,500 $64,200 $141,700 30% $103,900 $192,600 $408,300 30% $207,200 $374,400 $789,200
40% $22,300 $41,900 $85,200 40% $74,500 $129,900 $253,100 40% $150,200 $255,000 $491,800
50% $15,900 $30,400 $56,900 50% $57,600 $98,000 $168,900 50% $117,300 $193,600 $331,700
60% $12,500 $23,400 $43,900 60% $47,500 $78,300 $136,000 60% $97,700 $156,200 $267,200
70% $9,700 $19,000 $35,900 70% $40,400 $66,400 $111,100 70% $83,800 $133,100 $219,300
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $31,400 $51,300 $82,000 30% $103,000 $157,200 $246,000 30% $204,900 $306,100 $484,100
40% $20,700 $33,100 $57,700 40% $72,900 $108,300 $173,300 40% $148,100 $215,500 $344,700
50% $14,700 $23,400 $38,000 50% $57,000 $82,300 $124,600 50% $115,900 $165,500 $245,300
60% $11,100 $19,100 $30,900 60% $46,900 $67,300 $101,200 60% $97,200 $136,800 $201,300
70% $9,200 $14,500 $25,200 70% $38,800 $56,400 $82,700 70% $82,700 $114,600 $166,300
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $57,400 $73,700 $114,400 30% $172,300 $221,200 $343,400 30% $340,300 $436,900 $660,400
40% $36,300 $50,500 $64,200 40% $108,800 $151,600 $192,800 40% $220,500 $299,300 $380,800
50% $23,900 $30,700 $45,100 50% $84,700 $108,900 $135,300 50% $171,500 $220,600 $267,200
60% $19,200 $24,100 $29,900 60% $71,700 $85,400 $106,100 60% $141,700 $173,100 $209,400
70% $16,500 $20,800 $26,600 70% $61,600 $73,700 $94,400 70% $124,800 $153,100 $191,300
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21% 5% 10% 1% 5% 10% 1% 5% 10%
30% $49,400 $141,700 $3,671,900 30% $146,700 $397,300 ######### 30% $287,000 $763,600 #########
40% $30,700 $74,300 $230,900 40% $95,300 $213,200 $647,700 40% $187,100 $411,000 $1,237,200
50% $22,100 $48,800 $117,000 50% $71,600 $142,200 $328,200 50% $142,200 $277,400 $632,600
60% $16,900 $36,400 $79,100 60% $57,000 $110,400 $226,700 60% $114,800 $216,000 $437,100
70% $13,500 $28,900 $59,500 70% $47,900 $89,900 $173,500 70% $96,800 $177,000 $336,500
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $46,000 $108,400 $622,400 30% $138,000 $315,200 $1,737,200 30% $272,300 $608,800 $3,335,200
40% $28,500 $62,400 $177,300 40% $92,300 $181,400 $495,000 40% $183,200 $354,200 $955,700
50% $20,100 $42,000 $94,300 50% $68,200 $127,400 $274,300 50% $136,700 $248,700 $529,800
60% $15,500 $30,700 $64,000 60% $54,200 $96,000 $186,200 60% $110,500 $189,600 $361,600
70% $11,900 $24,100 $48,700 70% $45,400 $78,700 $146,100 70% $93,300 $155,400 $286,900
1% 5% 10% 1% 5% 10% 1% 5% 10%
30% $41,500 $75,500 $184,900 30% $133,100 $221,600 $543,000 30% $261,800 $435,900 $1,056,300
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Technical Appendix Fig. 2. Incremental cost-effectiveness ratios of DMOADs for OA prevention: ‘Knee injury only’ cohort.
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E. Losina et al. / Osteoarthritis and Cartilage 22 (2014) 415e430428were generally more favorable and are reported in Technical
Appendix Figs. 1 and 2, respectively. ICERs estimated for the
DMOAD regimen with base case parameters are highlighted in the
ﬁgures below.
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